First-of-its-kind liver cancer research

Health Industry Hub | July 13, 2020 |
[Total: 1    Average: 5/5]

Medical News: Primary liver cancer patients will benefit from a new research project in Western Australia that will apply the latest techniques to analyse patient tumours and test new treatments.

The research will be carried out through a new $10.8 million research centre which is made possible by a $5 million Cancer Research Trust grant and $5.8 million from Minderoo Foundation, Curtin University, The University of Western Australia, Harry Perkins Institute of Medical Research, the State Government and charitable organisations

Primary liver cancer is where a malignant cancer starts in the liver. It is responsible for the third-most cancer related deaths worldwide, behind only lung and stomach cancer.

Average survival after diagnosis is only 12 months and patients often present at an advanced stage when treatment options are limited.

Director of the Harry Perkins Institute of Medical Research, UWA Professor Peter Leedman said the research would be a true collaboration of medical specialists, experts in liver disease and cancer researchers.

“It will establish a process, where patient samples are analysed and tested with a range of potential treatments. Interestingly, the diagnosis of primary liver cancer has typically been made with a blood test and an MRI, but not with a biopsy.

“We now have the latest advanced genomics technology in Perth that can analyse a liver tumour biopsy at the single cell level and look at each tumour’s molecular fingerprint and individual pathology as well as compare a patient’s early and late stage cancer.

“By defining the underlying biology of each tumour, we will be able to provide more precision in treatment selection, eventually matching the ‘right patient to the right drug’ but we also expect to uncover new pathways that can be attacked with new drugs,” Professor Leedman said.

Selfcare In Healthcare Coalition on Mental Health Support in Pharma, Biotech and MedTech

Some patient tissue will undergo advanced genomics analysis by UWA Professor Alistair Forrest at the Harry Perkins Institute while Curtin University will use patient tissue to grow organoids, or mini livers.

Curtin University’s Associate Professor Nina Tirnitz-Parker said the new project aimed to improve outcomes for people with primary liver cancer.

“We can establish organoids, miniaturised versions of an organ, from patient tumour samples that will be profiled,” Associate Professor Tirnitz-Parker said.

“We will also establish a repository of organoids that represent different tumour subtypes and then perform drug screenings and make informed decisions on the best possible treatment choices without any side effects to the patient.”

The team aims to develop a unique large resource of approximately 500 liver cancer samples over five years from across Australia, which on a global scale is a sizeable collection.

“Most importantly, the project will make a difference to the treatment of liver cancer and contribute to greater international understanding of the disease,” she said.

The Western Australian Liver Cancer Collaborative will include more than 50 researchers from UWA, the Harry Perkins Institute of Medical Research and Curtin University-CHIRI. It will also involve Perth’s three main teaching hospitals as well as interstate and international collaborators.

WA Health Minister Roger Cook said it was a pleasure for the McGowan Government to contribute funding to The Western Australian Liver Cancer Collaborative, alongside eminent Western Australian institutions.

“Effective research is about more than giving dollars to help solve a problem,” Mr Cook said.

“That’s why it’s so heartening to see this truly collaborative Western Australian approach, with interstate and international input, applied to liver cancer research.

“The application of substantial combined effort, strategic thinking and the latest advanced genomics technology is sure to advance us much further on the path to unlocking the mysteries of this aggressive cancer that devastates far too many lives.”

Minderoo Foundation is providing $2.5 million, Curtin University $1 million, $500,000 is being contributed by each of UWA, the Harry Perkins Institute of Medical Research, the WA Health Department and the Sir Charles Gairdner Hospital Foundation. The McCusker Charitable Foundation is contributing $300,000.

Dr Steve Burnell, CEO of Minderoo Foundation’s Collaborate Against Cancer initiative said the new liver cancer collaborative was a crucial step to tackling this particularly deadly disease.

“At Minderoo Foundation we are passionate about enabling effective collaboration and supporting the collection and sharing of the data needed to underpin the next generation of cancer research and treatment,” Dr Burnell said.

“This project, generating a unique precision medicine dataset for liver cancer and involving dozens of experts across relevant disciplines, exemplifies this approach.”

About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Marketing & Strategy

Marketing Pharma Biotech Healthcare - PRIME Awards 2020 finalists announced

PRIME Awards 2020 finalists announced

Health Industry Hub | August 7, 2020 |

The finalists for PRIME Awards 2020 have been named, with winners to be announced via a virtual ceremony on Thursday […]


News & Trends - Pharmaceuticals

Pharma News - New Ventolin inhalers with dose counter reimbursed on the PBS

New Ventolin inhalers with dose counter reimbursed on the PBS

Health Industry Hub | August 7, 2020 |

Pharma News: GSK Australia is pleased to announce that a dose counter has been added to VENTOLIN (salbutamol sulfate) metered […]


News & Trends - Medical Technology

MedTech News - Siemens Healthineers to acquire Varian in $16.4bn deal

Siemens Healthineers to acquire Varian in $16.4bn deal

Health Industry Hub | August 5, 2020 |

MedTech News: Siemens Healthineers shall acquire Varian Medical Systems for approximately USD$16.4 billion. Since 2012, Siemens Healthineers and Varian have […]


News & Trends - Pharmaceuticals

Pharma News - New anti-cancer drug for prostate cancer

New anti-cancer drug for prostate cancer

Health Industry Hub | August 5, 2020 |

Pharma News: A new anti-cancer drug for prostate cancer overcomes the twin problems plaguing researchers for decades. It halts metastasis […]